Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 3/20 | 0.48 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.46 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLA1 | P09884 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | TXN | P10599 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 2/20 | 0.42 |
| ▸ | RAB9A | P51151 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12614443 | 0.86 | RAPGEF4 (0.59) | RAPGEF4EPHX1EPHX2MEN1MAPT | |
| SCHEMBL6076594 | 0.82 | EPHX1 (0.57) | RAPGEF4SOS1SLC2A1EPHX1EPHX2 | |
| SCHEMBL331059 | 0.80 | ALDH1A1 (0.59) | RAPGEF4EPHX1EPHX2NPY5RMEN1 | |
| SCHEMBL11547302 | 0.78 | CYP3A4 (0.56) | RAPGEF4EPHX1EPHX2NPY5RMAPT | |
| SCHEMBL29113772 | 0.78 | HSD17B10 (0.56) | RAPGEF4EPHX1EPHX2MEN1MAPT | |
| SCHEMBL395770 | 0.78 | ALDH1A1 (0.50) | MEN1MAPTKMT2AL3MBTL1TXN | |
| SCHEMBL15380326 | 0.77 | MAPT (0.46) | SOS1MEN1MAPTKMT2ATXN | |
| SCHEMBL10569557 | 0.77 | LMNA (0.54) | RAPGEF4EPHX1EPHX2MEN1MAPT | |
| SCHEMBL22103914 | 0.75 | TXN (0.35) | RAPGEF4SOS1MEN1MAPTKMT2A | |
| SCHEMBL6078208 | 0.75 | MEN1 (0.57) | MEN1MAPTKMT2AATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108440312-A | A kind of preparation method of 2- (3,4)-dichlorophenyl -4- fluoroanilines | 江苏科技大学 | 2018-08-24 | — | — | CN | claimed |
| US-12134603-B2 | Synthesis method for N-methyl-3-substituted methyl-4-pyrazolamide derivative and N-methyl-3-substituted methyl-4-pyrazolic acid | Shaoxing Shangyu Xin Yinbang Biochemical Co., Ltd. (CN) | 2024-11-05 | — | — | US | disclosed |
| US-20240083852-A1 | SYNTHESIS METHOD FOR N-METHYL-3-SUBSTITUTED METHYL-4-PYRAZOLAMIDE DERIVATIVE AND N-METHYL-3-SUBSTITUTED METHYL-4-PYRAZOLIC ACID | Shaoxing Shangyu Xin Yinbang Biochemical Co., Ltd. (CN) | 2024-03-14 | — | — | US | disclosed |
| CN-115141147-B | Synthesis method of N-methyl-3-substituted methyl-4-pyrazole formamide derivative | 绍兴上虞新银邦生化有限公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-115141147-A | Synthesis method of N-methyl-3-substituted methyl-4-pyrazole formamide derivative | 绍兴上虞新银邦生化有限公司 | 2022-10-04 | — | — | CN | disclosed |
| US-20180258038-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-09-13 | — | — | US | disclosed |
| CN-108440312-A | A kind of preparation method of 2- (3,4)-dichlorophenyl -4- fluoroanilines | 江苏科技大学 | 2018-08-24 | — | — | CN | disclosed |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2018-06-19 | — | — | US | disclosed |
| US-20170166524-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-06-15 | — | — | US | disclosed |
| US-9611214-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2017-04-04 | — | — | US | disclosed |
| EP-1881975-B1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2014-01-08 | — | — | EP | disclosed |
| EP-2407451-B1 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMA CO LTD (JP) | 2013-11-20 | — | — | EP | disclosed |
| US-20130203750-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-08 | — | — | US | disclosed |
| US-8420623-B2 | N, N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-04-16 | — | — | US | disclosed |
| US-20120065162-A1 | N-N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-03-15 | — | — | US | disclosed |
| EP-2407451-A1 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | Otsuka Pharmaceutical Co., Ltd. (JP) | 2012-01-18 | — | — | EP | disclosed |
| US-8084442-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-12-27 | — | — | US | disclosed |
| US-20090088406-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-04-02 | — | — | US | disclosed |
| EP-1881975-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-30 | — | — | EP | disclosed |
| WO-2006121218-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088406-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | RAPGEF4 1896/4885SOS1 4757/4885SLC2A1 1017/4885 |
| US-20130203750-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | RAPGEF4 1896/4885SOS1 4757/4885SLC2A1 1017/4885 |
| US-10000450-B2 | N,N-substituted 3-aminopyrrolidine compounds useful as monoamines reuptake inhibitors | SLC6A2, TPH1, SLC6A3 | RAPGEF4 1896/4885SOS1 4757/4885SLC2A1 1017/4885 |
| US-20180258038-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | RAPGEF4 1896/4885SOS1 4757/4885SLC2A1 1017/4885 |
| US-20170166524-A1 | N,N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | RAPGEF4 1896/4885SOS1 4757/4885SLC2A1 1017/4885 |
| US-20240083852-A1 | SYNTHESIS METHOD FOR N-METHYL-3-SUBSTITUTED METHYL-4-PYRAZOLAMIDE DERIVATIVE AND N-METHYL-3-SUBSTITUTED METHYL-4-PYRAZOLIC ACID | CYP2A13, CYP3A4, NISCH | RAPGEF4 1324/4885SOS1 4016/4885SLC2A1 3922/4885 |
| US-12134603-B2 | Synthesis method for N-methyl-3-substituted methyl-4-pyrazolamide derivative and N-methyl-3-substituted methyl-4-pyrazolic acid | CYP2A13, CYP3A4, NISCH | RAPGEF4 1324/4885SOS1 4016/4885SLC2A1 3922/4885 |
| US-20120065162-A1 | N-N-SUBSTITUTED 3-AMINOPYRROLIDINE COMPOUNDS USEFUL AS MONOAMINES REUPTAKE INHIBITORS | SLC6A2, TPH1, SLC6A3 | RAPGEF4 1874/4885SOS1 4751/4885SLC2A1 1025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.